GlobeNewswire Inc | Sep 28, 2020 08:00AM EDT

September 28, 2020

PITTSBURGH, Sept. 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the Chardan Virtual 4TH Annual Genetic Medicines Conference being held on October 5 - 6.

Conferences Details:Event: Chardan Virtual 4^TH Annual Genetic Medicines ConferenceFormat: Fireside ChatDate: Monday, October 5^THTime: 11:30 a.m. ETLocation: Webcast Link - or at the company?s website (click here)

About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBases designer PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:Dan FerryManaging DirectorLifeSci Advisors, LLCDaniel@lifesciadvisors.comOP: (617) 430-7576

NeuBase Media Contact:Cait Williamson, Ph.D.LifeSci Public Relationscait@lifescipublicrelations.comOP: (646) 751-4366